Glycosylated nanostructures in sublingual immunotherapy induce long-lasting tolerance in LTP allergy mouse model

Description

An effective specific immunotherapy should contain elements to generate specific recognition (T-cell peptides) and to modulate the immunological response towards a Th1/Treg pattern by enhancing dendritic cells (DCs). We propose a novel sublingual immunotherapy for peach allergy, using systems, that combine Prup3-T-cell peptides with mannose dendrons (D1ManPrup3 and D4ManPrup3). Peach anaphylactic mice were treated 1, 2 and 5 nM concentrations. Tolerance was assessed one/five weeks after finishing treatment by determining in vivo/in vitro parameters after challenge with Prup3. Only mice receiving D1ManPrup3 at 2 nM were protected from anaphylaxis (no temperature changes, decrease in Prup3-sIgE and -sIgG1 antibody levels, and secreting cells) compared to PBS-treated mice. Moreover, an increase of Treg-cells and regulatory cytokines (IL-10+/IFN-γ+) in CD4+-T-cells and DCs were found. These changes were maintained at least five weeks after stopping treatment. D1ManPrup3 is an effective new approach of immunotherapy inducing protection from anaphylaxis which persists after finishing treatment.

Abstract

Institute of Health Carlos III PI12/02481, PI15/00559 and PI18/00288

Abstract

RETICS ARADyAL RD16/0006/0001, RD16/0006/0003, RD16/0006/0011

Abstract

Sara Borrell Program CD14/00242

Abstract

Andalusian Regional Ministry of Economy and Knowledge CTS-7433

Abstract

Nicolas Monardes Program C-0044-2012 SAS2013

Abstract

Ministry of Economy and Competitiveness CTQ2014-52328-P, CTQ2017-86265-P, AGL2014-52395-C2-2

Abstract

European Regional Development Fund (ERDF)

Additional details